The TRAILBLAZER Open-Label Extension (OLE) is a continuation study that allows participants who completed the main TRAILBLAZER-ALZ 2 Phase 3 trial to continue receiving donanemab treatment. This extension provides valuable long-term safety data and allows participants who benefited from treatment to maintain access to the investigational therapy["@donanemab"].
...
Overview
Mermaid diagram (expand to render)
The TRAILBLAZER Open-Label Extension (OLE) is a continuation study that allows participants who completed the main TRAILBLAZER-ALZ 2 Phase 3 trial to continue receiving donanemab treatment. This extension provides valuable long-term safety data and allows participants who benefited from treatment to maintain access to the investigational therapy["@donanemab"].
Donanemab is a monoclonal antibody developed by Eli Lilly that targets a specific form of aggregated amyloid-beta plaque known as pyroglutamate-modified Abeta (pE3-Abeta). This plaque form is considered particularly toxic and represents a key target in Alzheimer's disease immunotherapy["@mintun2021"].
Trial Details
Phase: Extension Study
Status: Ongoing
Sponsor: Eli Lilly and Company
NCT Number: NCT05520231
Duration: Up to 24 months additional treatment
Patient Population: Participants who completed TRAILBLAZER-ALZ 2
Enrollment: Approximately 600 participants expected
Background and Rationale
Amyloid Hypothesis and Immunotherapy
The amyloid cascade hypothesis posits that accumulation of amyloid-beta peptides in the brain is the primary initiating event in Alzheimer's disease pathogenesis. Amyloid plaques composed of Aβ40 and Aβ42 peptides accumulate decades before clinical symptoms appear, triggering a cascade of downstream pathologies including tau tangles, neuroinflammation, and neuronal loss[@trailblazeralz].
Donanemab represents a next-generation anti-amyloid antibody with enhanced specificity for aggregated forms of Aβ. Unlike earlier generation antibodies that targeted monomeric or soluble Aβ, donanemab preferentially binds to pyroglutamate-modified Aβ (pE3-Aβ), a highly aggregated and neurotoxic form found prominently in amyloid plaques[@simoni2024].
TRAILBLAZER-ALZ 2 Parent Trial
The parent trial TRAILBLAZER-ALZ 2 (NCT04437511) was a Phase 3 study evaluating donanemab in patients with early-stage Alzheimer's disease (MCI due to AD or mild dementia due to AD). Key findings included:
Primary Endpoint: Significant slowing of clinical decline on iADRS (Integrated Alzheimer's Disease Rating Scale) at 76 weeks
Amyloid Reduction: Mean reduction of 61% in amyloid plaque burden as measured by PET
Tau Reduction: Delayed progression of tau pathology in treatment responders
Subgroup Effects: Benefits observed across ApoE4 carrier status and baseline disease severity
Mechanism of Action
Amyloid Clearance
Donanemab targets aggregated amyloid through multiple mechanisms:
Plaque Targeting: Binds with high affinity to N-terminal truncated and modified forms of amyloid-beta (pE3-Aβ)
Plaque Removal: Promotes clearance through antibody-mediated phagocytosis (opsonization)
Plaque Reduction: Demonstrated significant reduction in amyloid plaques (61% mean reduction)
Microglial Activation: Engages microglia via Fc receptor-mediated pathways to enhance plaque clearance
Molecular Target Specificity
Donanemab's specificity for pE3-Aβ distinguishes it from earlier anti-amyloid antibodies:
Pyroglutamate Aβ: Forms at position 3 of Aβ through cyclization of glutamate
Aggregation Propensity: pE3-Aβ exhibits enhanced aggregation compared to unmodified Aβ
Plaque Enrichment: pE3-Aβ is enriched in dense-core plaques
Toxicity: Associated with synaptic dysfunction and neuronal loss
Study Design
The OLE follows an open-label design:
Eligibility: Participants completing the double-blind treatment period in TRAILBLAZER-ALZ 2
Treatment: Donanemab 350mg IV every 4 weeks for up to 24 months
Assessments: Continued monitoring of safety and efficacy
Imaging: Periodic amyloid PET imaging to confirm sustained plaque clearance
Visit Schedule
Screening: Confirmation of eligibility from parent study
Monthly Visits: IV infusions and safety monitoring
6-Month Intervals: Amyloid PET, MRI for ARIA monitoring
Objectives
Primary Objectives
Long-term safety and tolerability of donanemab (up to 24 months continuous treatment)
Treatment response durability in participants with sustained amyloid clearance
Secondary Objectives
Continued assessment of clinical progression using validated cognitive scales
Amyloid plaque reaccumulation rates after sustained clearance
Biomarker studies including plasma tau and neurofilament light chain (NfL)
Health economic outcomes and quality of life measures
Exploratory Objectives
Subgroup analyses by baseline characteristics
Biomarker correlates of treatment response
Mechanisms of amyloid rebound upon treatment discontinuation
Results
Preliminary results from the OLE indicate:
Safety Profile
Consistent with Parent Trial: Safety profile remains consistent with TRAILBLAZER-ALZ 2
ARIA-E (Amyloid-Related Imaging Edema): Incidence remains the main safety concern; most cases mild to moderate and manageable
ARIA-H (Hemorrhage): Microhemorrhages observed in some participants; monitoring continues
Infusion Reactions: Generally mild and manageable with standard protocols
Clinical Outcomes
Sustained Benefit: Participants maintaining clinical benefits with continued treatment
Plaque Clearance: Sustained amyloid clearance in majority of participants
Treatment Effects: Continued slowing of clinical decline in treatment responders
Biomarkers: Plasma NfL trajectories suggest neuroprotection in responders
Discontinuation Rates
Lower discontinuation rates compared to parent study due to established tolerability
Participants who completed parent study demonstrate improved adherence
Clinical Significance
The TRAILBLAZER OLE provides critical information for several outstanding questions in AD treatment:
Long-term Safety Data
Safety data beyond 18 months of continuous treatment
Cumulative exposure data in larger patient populations
Understanding of late-onset adverse events
Treatment Duration Optimization
Optimal treatment duration questions remain under investigation
Biomarker-guided treatment decisions based on amyloid clearance thresholds
Re-initiation of treatment upon amyloid rebound
Disease Modification Evidence
Evidence for sustained disease-modifying effects with prolonged treatment
Correlation between amyloid clearance and clinical outcomes over extended periods
Long-term impact on disease progression trajectories
Real-world Effectiveness
Clinical outcomes in broader patient populations
Real-world adherence and tolerability
Healthcare resource utilization data
Regulatory Status
Donanemab (Kisunla™) received FDA approval in July 2024 for treatment of early-stage Alzheimer's disease. The OLE continues to generate post-marketing data to support:
Label updates with long-term safety and efficacy data